Abbott Laboratories (ABT)
106.17
+0.53
(+0.50%)
USD |
NYSE |
May 07, 16:00
106.01
-0.16
(-0.15%)
After-Hours: 20:00
Abbott Laboratories Enterprise Value: 191.94B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 06, 2024 | 191.94B |
May 03, 2024 | 192.40B |
May 02, 2024 | 192.43B |
May 01, 2024 | 193.07B |
April 30, 2024 | 192.52B |
April 29, 2024 | 194.78B |
April 26, 2024 | 195.23B |
April 25, 2024 | 194.07B |
April 24, 2024 | 194.12B |
April 23, 2024 | 195.34B |
April 22, 2024 | 194.43B |
April 19, 2024 | 194.80B |
April 18, 2024 | 191.30B |
April 17, 2024 | 192.40B |
April 16, 2024 | 198.15B |
April 15, 2024 | 197.60B |
April 12, 2024 | 197.98B |
April 11, 2024 | 202.05B |
April 10, 2024 | 201.56B |
April 09, 2024 | 203.77B |
April 08, 2024 | 200.43B |
April 05, 2024 | 201.62B |
April 04, 2024 | 199.72B |
April 03, 2024 | 201.75B |
April 02, 2024 | 203.04B |
Date | Value |
---|---|
April 01, 2024 | 203.16B |
March 31, 2024 | 205.89B |
March 28, 2024 | 204.85B |
March 27, 2024 | 204.53B |
March 26, 2024 | 201.10B |
March 25, 2024 | 198.51B |
March 22, 2024 | 199.48B |
March 21, 2024 | 201.11B |
March 20, 2024 | 201.10B |
March 19, 2024 | 203.98B |
March 18, 2024 | 202.73B |
March 15, 2024 | 208.02B |
March 14, 2024 | 213.85B |
March 13, 2024 | 216.12B |
March 12, 2024 | 217.16B |
March 11, 2024 | 216.18B |
March 08, 2024 | 217.51B |
March 07, 2024 | 217.44B |
March 06, 2024 | 214.70B |
March 05, 2024 | 213.21B |
March 04, 2024 | 215.92B |
March 01, 2024 | 213.45B |
February 29, 2024 | 213.49B |
February 28, 2024 | 215.93B |
February 27, 2024 | 214.81B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
124.99B
Minimum
Mar 23 2020
259.06B
Maximum
Dec 27 2021
195.95B
Average
196.92B
Median
Dec 19 2023
Enterprise Value Benchmarks
Stryker Corp | 134.46B |
Boston Scientific Corp | 115.19B |
Insulet Corp | 13.05B |
Intuitive Surgical Inc | 131.15B |
Edwards Lifesciences Corp | 50.24B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 1.225B |
Revenue (Quarterly) | 9.964B |
Total Expenses (Quarterly) | 8.578B |
EPS Diluted (Quarterly) | 0.70 |
Gross Profit Margin (Quarterly) | 55.21% |
Profit Margin (Quarterly) | 12.29% |
Earnings Yield | 3.02% |
Operating Earnings Yield | 3.42% |
Normalized Earnings Yield | 3.040 |